Alabama Medical Cannabis Sales to Commence in May After Five-Year Delay
Alabama will begin medical cannabis sales in early May, offering non-smokable products after years of legal delays and regulatory hurdles, with dispensaries preparing to serve qualified patients statewide
Key Points
- 1Alabama will begin medical cannabis sales in early May, five years after legalization approval
- 2Only non-smokable forms such as tablets, tinctures, oils, patches, and peach gummies are permitted
- 3Litigation and regulatory delays have slowed the rollout, but the first products are now being processed and tested
- 4Patients must register with the Alabama Medical Cannabis Commission and receive a physician's recommendation to access products
- 5As of this week, 43 physicians are certified to recommend medical cannabis in Alabama
Alabama's long-awaited medical cannabis program is finally moving forward, with the first patient products expected to reach dispensaries in early May. The program, initially approved by the state legislature nearly five years ago, faced significant setbacks due to litigation and regulatory challenges. Now, the cultivation, processing, and testing pipeline is underway, marking a pivotal moment for patients who have been waiting for access to medical cannabis treatments
Antoine Mordican, CEO of Native Black Cultivation, confirmed that he sent the state's first cannabis biomass to processor Homestead Health on April 10. However, Alabama's regulations remain among the strictest in the nation: "Alabama doesn’t allow anything smokable, so no flour, no vape. If you have to add heat to it, the state of Alabama don’t allow it," Mordican explained. Only tablets, tinctures, patches, oils, and a single peach-flavored gummy are permitted, with all raw or smokable products strictly prohibited
The journey from cultivation to dispensary is meticulous and highly regulated. Tyler Robinson, CEO of Homestead Health, described a multi-step testing protocol: "Once it comes back as a pass, we will start making it into a final product formulation. Once it’s in the final product formulation, we’ll send it back to testing." He anticipates that dispensaries could have products available by May 11, slightly later than the initial May 4 target, as testing and quality assurance remain top priorities
According to the Alabama Medical Cannabis Commission (AMCC), the entire process is tracked through a comprehensive seed-to-sale system. John McMillan, executive director of the AMCC, noted that the timeline for processing and dispensing is not entirely under the commission's control. As of this week, 43 physicians in Alabama are certified to recommend medical cannabis for patients with qualifying conditions such as cancer, chronic pain, PTSD, and terminal illnesses. Patients must register with the commission and obtain a physician’s recommendation before accessing products at dispensaries
Legal battles have contributed to the program's protracted rollout. Several lawsuits, including one from firms alleging discrimination in license awards and another from parents over access delays, have slowed progress—though the latter was dismissed last August. Robinson emphasized the impact on patients: "Ultimately, it’s the patients that have hurt the worst in all of this. It’s just unfortunate because we’re doing all we can on our end."
From OG Lab's perspective, Alabama’s imminent launch of medical cannabis sales is a significant milestone that could reshape the state's approach to patient care and cannabis regulation. The strict product limitations and extensive testing requirements signal a cautious regulatory environment, but the commitment from cultivators, processors, and physicians suggests a determined effort to meet patient needs. This development is worth watching as it may influence medical cannabis policies in other conservative states and set new standards for compliance and patient safety
